Crystalline Form C of tenofovir disoproxil salts thereof and a process for its preparation. The process involves adding a solution comprising tenofovir disoproxil and an organic solvent to salt-saturated water whereby the crystalline Form C of tenofovir disoproxil precipitates. The crystalline Form C of tenofovir disoproxil may be converted to a salt thereof. There is also provided a process for purifying a crude product comprising tenofovir monoisoproxil and tenofovir disoproxil.

The present invention relates to formulations of antiviral compounds in particular [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir PMPA) suitable for topical application and to their use in the reduction of or prevention of acquisition and transmission of herpes simplex virus.

The use of {9-[(R)-2-[[(S)-i[(S)-I (isopropoxvcarbonyl)etil]amino]phenoxvphosphinyl] -rnethoxy ]propyl ]adenine } and the henifinarate form (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition the combination of tenofovir alafenamide heniifumarate cobicistat emtricitabine and elvitegravir is disclosed.

-92 The use of the henifurmarate form of {9-[(R)-2-[[(S)-[[(S)-1 (isopropoxvcarbonyl)ethyllamino]phenoxvphosphinvl]methoxy]propyl]adenine } (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed In addition the combination of tenofovir alafenamide hemifiumarate cobicistat entricitabine and elvitegravir and the combination of tenofovir alafenamide hemifumarate cobicistat emtricitabine and darunavir are disclosed.

-94 The use of the henifurmarate form of {9-[(R)-2-[[(S)-[[(S)-1 (isopropoxvcarbonyl)ethyllamino]phenoxvphosphinvl]methoxy]propyl]adenine } (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed In addition the combination of tenofovir alafenamide hemifiumarate cobicistat entricitabine and elvitegravir and the combination of tenofovir alafenamide hemifumarate cobicistat emtricitabine and darunavir are disclosed.

The present invention relates to formulations of antiviral compounds, in particular [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), suitable for topical application, and to their use in the reduction of or prevention of acquisition and transmission of herpes simplex virus.

The use of {9-[(R)-2-[[(S)-[[(S)-l-(isopropoxycarbonyl)ethyl] amino]phenoxyphosphinyl] -methoxy]propyl] adenine } and the hemifumarate form (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition the combination of tenofovir alafenamide hemifumarate cobicistat emtricitabine and elvitegravir is disclosed.

The use of the hemifumarate form of {9-[(R)-2-[[(S)-[[(S)-l- (isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine} (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition the combination of tenofovir alafenamide hemifumarate cobicistat emtricitabine and elvitegravir and the combination of tenofovir alafenamide hemifumarate cobicistat emtricitabine and darunavir are disclosed.

The use of the hemifumarate form of {9-[(R)-2-[[(S)-[[(S)-l- (isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]methoxy]propyl]adenine} (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition the combination of tenofovir alafenamide hemifumarate cobicistat emtricitabine and elvitegravir and the combination of tenofovir alafenamide hemifumarate cobicistat emtricitabine and darunavir are disclosed.